Tesamorelin vs Argireline
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Tesamorelin
Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH). It is FDA-approved under the brand name Egrifta for reducing excess abdominal fat in HIV-infected patients with lipodystrophy.
Full details →Argireline
Argireline (Acetyl Hexapeptide-3) is a widely-used cosmetic peptide that reduces wrinkle depth by inhibiting neurotransmitter release. One of the first 'Botox-like' peptides developed for topical use.
Full details →Side-by-Side Comparison
| Aspect | Tesamorelin | Argireline |
|---|---|---|
| Mechanism | Stimulates the pituitary gland to produce and release growth hormone by binding to GHRH receptors. Increases IGF-1 levels which promotes lipolysis and reduces visceral adipose tissue. | Inhibits the formation of the SNARE complex required for neurotransmitter release, reducing the intensity of muscle contractions that cause expression lines. |
| Typical Dosage | FDA-approved dose: 2mg administered subcutaneously once daily. Research protocols may use various dosing schedules. | Topical: 5-10% concentration in serums, applied twice daily. Higher concentrations used in professional treatments. |
| Administration | Subcutaneous injection into the abdomen. Rotate injection sites. Best administered at the same time daily, preferably in the evening. | Topical application to clean skin. Most effective on expression lines (forehead, crow's feet). Consistent use required for visible results. |
| Side Effects | Common side effects include injection site reactions (erythema, pruritus), joint pain, peripheral edema, and muscle pain. May cause elevated blood glucose. | Generally very well-tolerated. Occasional mild irritation or dryness. No systemic absorption at cosmetic doses. |
| Best For |
What They Have in Common
Both Tesamorelin and Argireline are commonly used for: